On-Label Persistence in Psoriasis After Switching to Guselkumab or Tumor Necrosis Factor Inhibitors from Other Advanced Therapies

Maryia Zhdanava¹, Timothy P. Fitzgerald², Porpong Boonmak¹, Dominic Pilon¹, Samuel Schwartzbein¹, Béatrice Libchaber¹, Steven Feldman³ ¹Analysis Group, Inc., Montréal, QC, Canada; ²Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA; ³Wake Forest School of Medicine, NC, USA

Background



Switching between psoriasis therapies is part of a management strategy to improve clinical outcomes, especially when a prior therapy has limited effectiveness or leads to an adverse reaction¹



Evidence of guselkumab's (GUS) superior benefits compared to a commonly used subcutaneous tumor necrosis factor inhibitor (SC TNFi) adalimumab has been established; however, little is known about the relative performance of GUS versus SC TNFi in the subset of patients (pts) who switch to these therapies²

Persistence while receiving labeled dosing is a useful proxy for real-life drug performance, = as poor performance may reflect either discontinuation or dose escalation³

Objectives

To compare real-world persistence among pts with psoriasis switching to treatment with US labeled dosing for GUS versus any SC TNFi

Results

1,037 pts were included in the GUS cohort and 345 pts in the SC TNFi cohort; characteristics at baseline were well-balanced

Weighted baseline characteristics	GUSª (N=1,037)	TNFi ^a (N=345)	Std. diff.ª %	Weighted baseline characteristics	GUSª (N=1,037)	TNFi ^a (N=345)	Std. diff.ª %
Demographics				Characteristics			
Age at index date (years), mean ± SD [median]	47.2 ± 11.9 [48.6]	47.2 ± 11.6 [48.7]	0.1	Quan-Charlson comorbidity index, mean ± SD [median	0.3 ± 0.8 [0.0]	0.3 ± 0.8 [0.0]	0.0
Female	54.7	54.7	0.0	Common comorbidities			
Region of residence at index date				Hypertension	33.1	31.9	2.6
				Hyperlipidemia	31.1	30.1	2.2
South	47.0	47.0	0.0	Obesity	25.0	24.8	0.5
Midwest	29.0	29.0	0.0	Index advanced therapy			
Northeast	16.7	16.7	0.0	GUS	100.0	-	-
West	7.3	7.3	0.0	Adalimumab	_	79.9	-
				Certolizumab Pegol	-	14.9	-
Unknown	0.0	0.0	0.0	Etanercept	+-C)	4.2	-
Payer				Infliximab		1.0	-
Commercial	66.4	65.4	2.2	Advanced therapy being switched from			
Self-insured	31.4	32.3	1.9	Biologics	78.5	78.5	0.0
Medicare, Medicaid, or unknown	2.1	2.3	1.4	Ustekinumab	29.3	29.3	0.0
	۵.۱	2.0	1. 1	Secukinumab	23.1	26.0	6.6
Index year				Ixekizumab	13.3	10.7	7.8
2017	9.6	9.6	0.0	Risankizumab	10.9	11.0	0.3
2018	19.1	19.1	0.0	Tildrakizumab	1.6	1.5	0.7
2019	16.8	16.8	0.0	Brodalumab	0.3	0.0	8.1
2020	14.7	14.7	0.0	Small-molecule drugs	21.5	21.5	0.0
				Apremilast	21.3	21.5	0.6
2021	19.8	19.8	0.0	Deucravacitinib	0.2	0.0	6.8
2022	13.3	13.3	0.0	All-cause pharmacy costs⁵, mean ± SD [median]	45,947 ± 25,164 [45,202]	46,712 ± 27,491 [43,943]	2.9
2023	6.6	6.6	0.0	All-cause medical costs ⁵, mean ± SD [median]	7,231 ± 13,969 [1,912]	6,465 ± 12,420 [1,635]	5.8

Data shown are % unless otherwise noted. a Cohorts were balanced using overlap propensity score weighting based on demographics, region, index year, prevalence of comorbidities, treatments, healthcare resource use, and pharmacy and medical costs. deviation: **USD**=United States Dollar.

Methods

- Data from the IQVIA PharMetrics[®] Plus database were used (01/01/2016 - 12/31/2023)
- Index date was the first observed claim for GUS or SC TNFi after switching from another systemic advanced therapy
- Baseline period included the 12 months before the index date; follow-up period spanned the start of the maintenance phase until the earliest of end of data
- availability or end of continuous health plan eligibility • The maintenance phase commenced, based on product
- label, at the time of a specific dose following initiation: GUS: the 3rd dose
- Adalimumab: the 2nd dose
- Certolizumab pegol: the 4th dose
- Etanercept: the 7th dose

Infliximab: the 4th dose

Study sample


Pts eligible for inclusion were/had:

- adults switching to GUS or SC TNFi during the intake period (i.e., 07/13/2017 - 06/30/2023) from another psoriasis-indicated advanced therapy
- naïve to both GUS and SC TNFi before the switch
- ≥12 months of continuous health plan eligibility before the index date
- ≥ 2 claims with a diagnosis of psoriasis vulgaris on separate dates during the baseline period or on the index date
- persistent on the index biologic (as defined below) between the index date and start of the maintenance phase
- no claims for rheumatoid or psoriatic arthritis, inflammatory bowel disease, or other autoimmune disorders during the baseline period



Outcomes and statistical analyses

- Overlap propensity score weights were used to balance baseline characteristics between the GUS and SC TNFi cohorts; balance was assessed using standardized differences (std. diff.; <10% considered wellbalanced)⁴
- Persistence while receiving on-label US maintenance dosing was assessed from the start of the maintenance phase by weighted Kaplan-Meier (KM) analysis and Cox proportional hazard models
- Persistence was defined as no gaps in treatment supply >120 days for GUS and infliximab (twice the 8-week maintenance dosing interval) or >60 days for adalimumab, certolizumab pegol, and etanercept (twice the typical dispensing interval of 4 weeks). A sensitivity analysis was conducted using a gap >120 days for all agents; the last day of index agent supply before the gap defined the discontinuation date - Continuing on labeled US maintenance dosing was defined as maintaining the following fixed doses: 100
- mg/8 weeks for GUS, 40 mg/2 weeks for adalimumab, 50 mg/week for etanercept. For agents with weight-dependent dosing (i.e., certolizumab pegol and infliximab), the first maintenance dose was used as the reference dose; pts were censored at the first instance of any dose change
- Pts who did not change dose or discontinue treatment during the follow-up period were censored on the last day of index treatment supply before the end of the follow-up period



Key Takeaways

Among pts with psoriasis who switched advanced treatments, those switching to GUS displayed higher persistence while receiving on-label dosing compared to those who switched to SC TNFi



Findings were consistent across multiple gap length definitions and time points



GUS may provide better long-term disease control than SC TNFi among pts who switch from other advanced therapies